Enzon Pharmaceuticals, Inc. (ENZN)
- Previous Close
0.0886 - Open
0.0949 - Bid --
- Ask --
- Day's Range
0.0886 - 0.0949 - 52 Week Range
0.0600 - 0.2200 - Volume
20,245 - Avg. Volume
17,682 - Market Cap (intraday)
7.043M - Beta (5Y Monthly) --
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 30, 2019
- 1y Target Est
--
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
enzon.comRecent News: ENZN
Performance Overview: ENZN
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENZN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENZN
Valuation Measures
Market Cap
7.04M
Enterprise Value
-38.95M
Trailing P/E
31.87
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.14
Enterprise Value/Revenue
-1.56k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-1.45%
Return on Equity (ttm)
3.24%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
221k
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
45.99M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-666.12k
Research Analysis: ENZN
Company Insights: ENZN
ENZN does not have Company Insights